Remote or partly-remote trials that use technologies such as bring your own device (BYOD), electronic patient-reported outcomes (ePRO), and direct data capture (DDC) have evolved from novelties to proven and valuable necessities.
While the idea of a clinical trial that uses technology to reduce the number of in-person site visits is simple enough, design and implementation are not.
In this article for the Journal of Clinical Studies, Clinical Ink Chief Business Officer Jonathan Andrus discusses practical considerations for adopting decentralized trials, as well as how these models reduce costs, deliver cleaner data, and improve patient acceptance and engagement.
